National Cancer Institute, NIH, 9609 Medical Center Drive, Bethesda, MD 20892, USA.
German Cancer Research Center (DKFZ), Im Neuenheimer Feld 242, 69120 Heidelberg, Germany.
Cancer Epidemiol. 2016 Jun;42:46-52. doi: 10.1016/j.canep.2016.03.003. Epub 2016 Mar 21.
Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized.
Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n=25).
63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n=6] and 100% [95% CI: 60-100%, n=4] compared to 0% (n=2) and 0% (n=13) for non-OPC cases.
HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.
人乳头瘤病毒 16 型（HPV16）E6 抗体是口咽癌（OPC）有前途的生物标志物；然而，非 OPC 病例的血清阳性率尚未得到很好的描述。
2003 年至 2006 年间，匹兹堡大学诊断的 260 例（38 例 OPC，222 例非 OPC）头颈部癌症的治疗前血清用于检测 HPV16（L1、E1、E2、E4、E6、E7）和非 HPV16 E6（HPV6、11、18、33）抗体。在已知 HPV 状态的肿瘤（n=25）中评估 HPV16 E6 抗体对 HPV 驱动肿瘤的敏感性和特异性。
63.2%的 OPC 病例与 27.5%的非 OPC 病例为 HPV16 血清阳性；HPV16 E6 血清阳性率分别为 60.5%和 6.3%，比值比为 22.8（95%置信区间[CI]：9.8-53.1）。HPV16 E6 抗体对 HPV 驱动的 OPC 的敏感性和特异性分别为 100%（95%CI：50-100%；n=6）和 100%（95%CI：60-100%，n=4），而非 OPC 病例分别为 0%（n=2）和 0%（n=13）。
HPV16 抗体在 OPC 病例中明显比非 OPC 病例更为常见，尤其是 HPV16 E6 抗体。
